Methods relating to aromatase inhibitor pharmacogenetics
AssigneeThe Penn State Research Foundation
InventorsPhilip Lazarus, Dongxiao Sun
Life of this patent
Estimating the term…
Abstract
Methods for aiding in determining therapeutic efficacy of an aromatase inhibitor in a subject are provided according to embodiments of the present invention which include detecting expression and/or function of at least one UDP-glucuronosyltransferase having activity to modify at least one aromatase inhibitor and/or metabolite of the aromatase inhibitor by glucuronidation, wherein detection of expression and/or function of the UDP-glucuronosyltransferase is correlated with therapeutic efficacy of the aromatase inhibitor in the subject. Detection of UDP-glucuronosyltransferase expression and/or function includes detection of a UDP-glucuronosyltransferase gene deletion polymorphism in the subject.
Claims18
A method for aiding in determining therapeutic efficacy of exesmestane in a subject who has or is at risk of having a condition or disease for which inhibition of aromatase is desirable to decrease estrogen in the subject, comprising:
- assaying a biological sample obtained from the subject for a UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism, wherein detection of the UDP glucuronosyltransferase 2 family, polypeptide B17gene deletion polymorphism is correlated with altered therapeutic efficacy of the exesmestane in the subject compared to a control subject;
- and
- treating the subject with exemestane based on a result of assaying the biological sample where the subject is determined to have no UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism or determining an alternative treatment without exemestane based on a result of assaying the biological sample where the subject is determined to have a UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism.
A kit for aiding in determining therapeutic efficacy of exemestane in a subject, comprising:
- at least one reagent for detection of a UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism in a sample obtained from the subject;
- and
- at least one reagent for detecting aromatase in the sample obtained from the subject.
A method of detecting exesmestane use in a subject, comprising:
- assaying a biological sample obtained from the subject for a UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism, wherein detection of the UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism is correlated with decreased production of glucuronidated 17-dihydroexemestane in the urine of the subject, wherein detecting no UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism supports a finding of no exemestane use in the subject when glucuronidated 17-dihydroexemestane is not detected in urine;
- and
- assaying a blood sample obtained from the subject for exemestane where the assaying detects a UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism.
A method for aiding in determining therapeutic efficacy of an aromatase inhibitor in a subject who has or is at risk of having a condition or disease for which inhibition of aromatase is desirable to decrease estrogen in the subject, comprising:
- detecting expression and/or function of at least one UDP-glucuronosyltransferase having activity to modify at least one aromatase inhibitor and/or metabolite of the aromatase inhibitor by glucuronidation, wherein detection of expression and/or function of the UDP-glucuronosyltransferase is correlated with therapeutic efficacy of the aromatase inhibitor in the subject;
- and
- selecting a treatment for the subject based on detecting expression and/or function of at least one UDP-glucuronosyltransferase having activity to modify at least one aromatase inhibitor and/or metabolite of the aromatase inhibitor by glucuronidation.
Dependencies are inferred from the claim text.